Aspirinin hepatotoksik etkisi ve Reye sendromu

Nergiz Turgut; Tülin Söylemezoğlu

Aspirinin hepatotoksik etkisi ve Reye sendromu

Year 2011, Volume: 33 Issue: 1, 125 - 132, 14.03.2011

Nergiz Turgut , Tülin Söylemezoğlu

Abstract

Özet

Analjeziklerin riskleri ve yararları hakkındaki tartışmalar, analjezikler ilk çıktıklarından beri devam etmektedir. Araştırmacılar hem yeni hem de eskiden denenmiş ve kontrol edilmiş ilaçların, kontrendikasyonlar ve yan tesirler açısından yeniden düzenlemelere maruz kalmaları ile ilgilenmektedir. Bu derlemede, piyasaya giren birçok ilaca karşın halen yaygın olarak kullanılan ve bu gruptaki diğer ilaçlarla değerlendirmek ve karşılaştırmak açısından standart olarak kullanılan aspirinin, hepatotoksik etkisi sunulmaktadır. Ayrıca viral enfeksiyonlar sırasında aspirin kullanılması ile ilişkili olabileceği ileri sürülen, yağlı karaciğer dejenerasyonunun eşlik ettiği bir akut ensefalit olan Reye sendromu sunulmaktadır.

Anahtar sözcükler: Aspirin, salisilat, hepatotoksik etki, Reye sendromu

Abstract

Discussions about the risks and benefits of analgesics have been continuing since the first come out of analgesics. Investigators are interested in new arrangements for contraindications and side effects of both new and previously checked and controlled drugs. In this review, the hepatotoxic effect of aspirin which is currently used widespread besides availability of many drugs in market and also which is used as a standard to evaluate and to compare to other drugs is presented. In addition, Reye's syndrome; an acute encephalopathy accompanied with fatty liver degeneration which suggested to be associated with aspirin usage during viral infections is presented.

Key words: Aspirin, salicylate, hepatotoxic effect, Reye's syndrome

Keywords

References

Roberts LS, Marrow JD. Analgesic-Antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Limbird LE, Hardman JG (Eds). Goodman and Gilman’s The pharmacological basis of therapeutics. 10th ed. USA: The Mcgraw-Hill Companies, 2001; pp 687-703.
Nietch P: Aspirinin Terapötik Uygulamaları. Zichner R (Eds).(çeviri) Bayer Türk San. Ltd. Şti. İstanbul: 1991; pp 7-67.
Gosselin RE, Smith RP, Hodge HC, Braddock JE. Salicylate. In:Tracy TM (Eds). Clinical Toxicology of Commercial Products, 5th Ed. London:Williams and Wilkins,1984; pp 368-75.
Kayaalp, S.O: Non steriodal anti inflamatuvar ilaçlar. Rasyonel Tedavi yönünden Tıbbi Farmakoloji. Cilt 2, 9. Baskı, Ankara: Feryal Matbaacılık San ve Tic. Ltd.Şti., 2000; pp 1032-39.
Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet 1985; 10: 164-77.
Goldfrank LR, Bresnitz EA, Hartnett L, Flomenbaum NE. Salicylates. In:Goldfrank LR (Eds). Goldfranks’ toxicologic emergencies, 4th ed. New york: Prentice-Hall International Inc. 1990; pp 261-9.
Benson GD. Hepatotoxicity following the therapeutic use of antipiretic analjesics. Am J Med 1983 14; 75: 85-93.
Cersosimo RJ, Matthews SJ. Hepatototoxicity associated with choline magnesium trisalicylate: Case report and review of salicylate induced hepatotoxicity. Drug Intell Clin Pharm 1987; 21: 621-5.
Prescott LF. Effects of non-narcotic analgesics on the liver. Drugs 1986; 32: 129- 47.
Nydick I, Tang J, Stollerman GH, Wroblewski F, Ladue JS. The influence of rheumatic fever on serum concentrations of the enzyme, glutamic oxaloacetic transaminase. Circulation 1955; 12: 795-806.
Manso C, Nydick I. Taranta A. Effect of aspirin administration on serum glutamic oxaloaacetic and glutamic pyruvic transaminases in children. Proc Soc Exp Biol Med 1956; 93: 84-8.
Drivsholm A, Madsen S. The influence of treatment with sodium salisylate on the serum glutamic oxaloacetic transaminase activity. Scand J Clin Lab Invest 1961; 13: 442-6.
Okumara H, Ichikawa T, Obayashi K, Aramaki T. Studies on aspirin induced hepatic injury. Rec Adv Gastroenterol 1967; 3: 223.
Russell AS, Sturge RA, Smith MA. Serum transaminases during salicylate therapy. Br Med J 1971; 2: 428-9.
Zimmerman H J. Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981; 141: 333-42.
O’Conner N, Dargon PI, Jones AL. Hepatocellular damage from non-steriodal anti-inflammatory drugs. QJM 2003; 96: 787-91.
Fry SW, Seef LB. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North Am 1995; 24: 875-905.
Rich RR, Johnson JS. Salicylate hepatotoxicity in patients with rheumatoid arthritis. Arhritis Rheum 1973;16: 1-9.
Tolman KG, Peterson P, Gray BS, Hammer SP. Hepatotoxicity of salicylates in monolayer cell cultures. Gastroenterology 1978; 74: 205-8.
Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly 2010; 140: w13080. doi: 10.4414/smw.2010.13080.
Karademir S, Oguz D, Senocak F, Ocal B, Karakurt C, Cabuk F. Tolmetin and salicylate therapy in acute rheumatic fever: Comparison of clinical efficacy and side-effects. Pediatr Int 2003; 45: 676-9.
Zucker P, Daum F, Cohen MI. Aspirin hepatitis. Am J Dis Child 1975; 129: 1433-34.
Bernstein BH, Singsen BH, Kinng KK, Hanson V. Aspirin induced hepatotoxicity and its effect on juvenile romatoid artritis. Am J Dis Child 1977; 131: 659-63.
Miller JJ, Weissman DB. Correlations between transaminase concentrations and serum salicylate concentrations in juvenile rheumatoid artritis. Arthritis Rheum 1976; 19: 115-8.
Athreya BH, Moser G, Cecil HS, Myers AR. Aspirin induced hepatotoxicity in juvenile rheumatoid arthritis: A prospective study. Arthritis Rheum 1975; 18: 347-52.
Wu D, Ceberbaum A. Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes. Mol Pharmacol 2001; 59: 795-805.
Manov I, Motanis H, Frumin I, Iancu TC. Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrasructural aspects. Acta Pharmacol Sin 2006; 27: 259-72.
Garber E, Craig RM, Bahu RM. Letter: Aspirin hepatotoxicity. Ann Intern Med 1975; 82: 592-3.
Levy M. Adverse reactions to over the counter analgesics: An epidemiological evaluation. Agents Actions Suppl. 1988; 25: 21-31.
Pugliese A, Beltroma T, Torre D. Reye’s and Reye’s -like syndromes. Cell Biochem Funct 2008; 26: 741-6.
Beutler AI, Chesnut GT, Mattingly JC, Jamieson B. FPIN’s Clinical Inquiries. Aspirin use in children for fever or viral syndromes. Am Fam Physician 2009 15; 80: 1472.
Sillanpaa M, Makela, AL, Koivikko, A. Acute liver failure and encephalopathy (Reye’s syndrome?) during salicylate therapy. Acta Paediatr Scand. 1975; 64: 877-80.
Starko KM, Ray CG, Dominguez LB, Stromberg W L, Woodhall DF. Reye’s Syndrome and salicylate use. Pediatrics 1980; 66: 859-64.
Ghosh A, Pradhan S, Swami R, K C SR, Talwar OP. Reye Syndrome: a case report with review of literature. JNMA J Nepal Med Assoc 2008; 47: 34-7.
Glen-Bott AM. Aspirin and Reye’s syndrome: a reappraisal. Med Toxicol Adverse Drug Exp 1987; 2: 161-5.
Schrör K. Aspirin and Reye Syndrome: a review of the evidence. Paediatr Drugs 2007; 9: 195-204.
Glasgow JF. Reye’s syndrome: the case for a casual link with aspirin. Drug Saf 2006; 29: 1111-21.
Hall SM. Reye’s sendrome and aspirin; a review. Br J Clin Pract Suppl 1990; 70: 4-11.
Pugliese A, Beltramo T, Torre D. Reye’s and Reye’s-like syndromes. Cell Biochem Funct 2008; 26: 741-6
Hurwitz ES, Baret MJ, Bergman D. Gunn WJ, Pinsky P, Schonberger LB, Drage JS, Kaslow RA, Burlington DB, Quinnan GV, et al. Public health service study of Reye’s Sendrome and medications. Report of the main study. JAMA 1987; 257: 1905-11.
Glasgow JF, Middleton B. Reye syndrome--insights on causation and prognosis. Arch Dis Child 2001; 85: 351-3.
Casteels-Van Daele M. Reye syndrome or side-effects of anti-emetics? Eur J Pediatr 1991; 150: 456-9.
Kamienski MC. Reye syndrome. Am J Nurs 2003; 103: 54-7.
Cooper C. Would you recognize this syndrome? RN 2003; 66: 49-52.